For example, seven patients, who were treated with etanercept, adalimumab, or rituximab, improved and had SAA suppression after tocilizumab therapy, and one patient, who was treated with a TNF inhibitor and tocilizumab, achieved remission with abatacept.[30,42] This suggests that biologic agents need to be replaced to suppress the progression of AA amyloidosis secondary to RA, depending on the patient. Here, TNF is linked to AA amyloidosis.